How to identify biotech diamonds in the rough

Discipline, experience and caution required

clock • 4 min read

There are currently 150 Nasdaq-listed biotechnology companies trading at an enterprise value of or below zero, where the value of the company is equal to or less than the amount of cash on its balance sheet. This is the greatest number of businesses in this situation in the sector for 15 years.

To continue reading this article...

Join Investment Week today

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Equities

Zennor Asset Management's Harry Salter: Japanese equity market the haystack in the needle

Zennor Asset Management's Harry Salter: Japanese equity market the haystack in the needle

Postcard from Japan

Harry Salter
clock 16 November 2026 • 4 min read
JB Beckett: Anthropic is the anomaly in the machine

JB Beckett: Anthropic is the anomaly in the machine

Ahead of IPO

JB Beckett
clock 12 November 2026 • 3 min read
Anthropic bankers preparing to increase IPO valuation to $1.5trn – reports

Anthropic bankers preparing to increase IPO valuation to $1.5trn – reports

Draft prospectus filed on Tuesday

Jack Roach
clock 11 November 2026 • 2 min read
Trustpilot